TrialsgrambetaRCTs are beautiful

Clostridioides difficile

Fidaxomicin vs. vancomycin (Louie), faecal microbiota transplantation (van Nood) and bezlotoxumab (MODIFY).

  • 2017MODIFY I/II⁠Recurrence preventionIn 2,655 patients receiving antibiotics for Clostridium difficile infection, a single dose of bezlotoxumab reduced recurrent CDI at 12 weeks compared with placebo.Read →
  • 2013van Nood FMT⁠Recurrent CDIIn 43 patients with recurrent Clostridium difficile infection, faecal microbiota transplantation achieved cure more often than oral vancomycin.94% vs 31%Read →
  • 2011Louie Fidaxomicin⁠Initial therapyIn 629 patients with Clostridium difficile infection, fidaxomicin reduced recurrence at 4 weeks compared with oral vancomycin with similar clinical cure.15.4% vs 25.3%Read →